IP Library › Granted Patent US 9,125,848
Granted Patent B2
US 9,125,848 · App. 13/157,990 · Granted Sep 8, 2015

Alpha lactalbumin immunization methods

Inventors: Vincent K. Tuohy (Broadview Heights, OH); Justin M. Johnson (Willoughby Hills, OH); Ritika Jaini (Cleveland, OH)
Assignee: The Cleveland Clinic Foundation
A61K39/0011A61K2039/572
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,125,848
App. No.
13/157,990
Granted
Sep 8, 2015
Kind
B2
Abstract

Compositions and methods for immunization against human breast cancer are disclosed. A breast cancer vaccine comprises an immunogenic polypeptide comprising human α-lactalbumin.

Claims (10)

1. A method of immunizing a non-lactating female human patient against a human α-lactalbumin, the method comprising the step of inducing an immune response against α-lactalbumin in said patient by administering to the patient an immunogenic composition, said composition comprising an adjuvant; and a purified recombinant polypeptide consisting of a human α-lactalbumin sequence as set forth in SEQ ID NO: 1.

2. The method of claim 1 , wherein T cells are activated after administration of the polypeptide to the patient.

3. The method of claim 2 , wherein the T cells are CD4 + .

4. The method of claim 2 , wherein the T cells are CD8 + .

5. The method of claim 1 , wherein a proinflammatory immune response is induced by subsequent encounter of immune cells with α-lactalbumin.

6. The method of claim 5 , wherein the proinflammatory immune response comprises production of IFNγ by T cells.

7. The method of claim 5 , wherein the proinflammatory immune response is breast tissue specific.

8. The method of claim 1 , wherein said patient has a breast tumor that overexpresses α-lactalbumin.

9. The method of claim 1 , wherein the adjuvant is GPI-0100.

10. The method of claim 1 , wherein the recombinant polypeptide is produced in Escherichia coli.

Assignments (3)
CONFIRMATORY LICENSE Recorded May 4, 2017
From: CLEVELAND CLINIC FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 042402/0205 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2015
From: TUOHY, VINCENT K.
To: THE CLEVELAND CLINIC FOUNDATION
Reel/Frame 036253/0846 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2015
From: JOHNSON, JUSTIN M.; JAINI, RITIKA
To: THE CLEVELAND CLINIC FOUNDATION
Reel/Frame 036185/0648 →
Continuity (4)
Provisional Application 61353825 · Jun 11, 2010
Provisional Application 61353464 · Jun 10, 2010
Provisional Application 61353470 · Jun 10, 2010
Related Publication 20120003254A1 · Jan 5, 2012